BiotechTube
Home/XOMA/Natasha Hernday
NH

Natasha Hernday

Executive Director, Corporate Operations & Marketing

XOMA

Therapeutic Areas

OphthalmologyImmunologyPainRare DiseasesEndocrinology

XOMA Pipeline

DrugIndicationPhase
Teprotumumab (Tepezza)Thyroid Eye Disease (TED)Approved
VX-548Acute PainPhase 3
Ritlecitinib (Litfulo)Alopecia AreataApproved
GevokizumabNon-infectious UveitisPhase 3
BertilimumabBullous PemphigoidPhase 2
XOMA 358 (RZ358)Congenital HyperinsulinismPhase 2

Leadership Team at XOMA

JR
James R. Neal
Interim Chief Executive Officer
T(
Thomas (Tom) Burns
Chief Financial Officer and Corporate Secretary
BS
Bradley Sitko, CFA
Chief Investment Officer
OH
Owen Hughes
Executive Director
BK
Barbara Kosacz
Chairperson of the Board of Directors
M(
Matthew (Matt) W. Perry
Director
BK
Bruce Kovner
Director
A(
Andrew (Andy) D. Sandler
Director
K(
Katherine (Kathy) L. Younker
Director
SL
Susan L. Kelly
Director
View full XOMA profile